Abstract. Re-programming of lipogenic signaling is one of the most significant alterations of tumor cell pathology. Consistent with a large demand for lipids, tumor cells express high levels of lipogenic enzymes, most of which are transcriptional targets of sterol regulatory element-binding protein 1 (SREBP1). However, the expression levels and the function of SREBP1 in ovarian cancer are largely unknown. Our study aimed to assess the oncogenic potential of SREBP1 in ovarian cancer. In this study, we showed that the SREBP1 protein expression was significantly higher in human ovarian cancer compared to benign and borderline ovarian tumors by immunohistochemical staining. Knockdown of SREBP1 by small hairpin RNA (shRNA) in ovarian cancer cells retarded cell growth, migration and invasion and enhanced cell apoptosis without significant effects on cell cycle distribution. In a xenograft SCID mouse model, SREBP1 silencing inhibited tumor growth in vivo and reduced the expression of SREBP1 downstream lipogenic genes at both the protein and mRNA levels. Taken together, the results from this study demonstrate a crucial role of SREBP1 in ovarian cancer growth, which establish SREBP1 as a novel therapeutic target for antitumor therapy.
Introduction
Ovarian cancer is the third most common gynecologic malignancy and is the most lethal form of gynecological cancer. Aberrations of metabolic pathways are the characteristic physiological changes occurring in cancer cells. In the 1920s, Warburg (1) discovered that cancer cells reprogram energy production mechanism through high aerobic glycolysis. Furthermore, it was found that cancer cells derive most fatty acids from de novo synthesis (2) . Cancer is a complex blend of genetic and metabolic perturbations and de novo lipogenesis is believed to be active in oncogenesis. Expression of most enzymes required for the synthesis of fatty acids, cholesterol, triacylglycerols and phosphoglycerides is regulated by the SREBPs which have now been established as global lipid synthetic regulators (3, 4) . The SREBPs have many targets such as fatty acid synthase (FASN), ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACAC) and stearoyl-CoA desaturase-1 (SCD1) (5) (6) (7) (8) . The regulatory function of sterol regulatory element-binding protein 1 (SREBP1) indicates a role in sensing and regulating cancer-associated lipogenesis. Altered expression of SREBP1 has been reported in various human cancers, such as hepatocellular carcinoma, colorectal carcinoma, breast and prostate cancers (9) (10) (11) (12) . However, the functional studies on the role of SREBP1 in human ovarian cancer are limited to date.
In this study, we investigated the relationship between SREBP1 expression levels and ovarian cancer. We studied the association between expression of SREBP1 in ovarian cancer and its effect on ovarian cancer progression and metabolic changes in vitro and in vivo.
Materials and methods

Ovarian cancer specimen and immunohistochemical (IHC)
staining. Human ovarian tumor specimens were obtained from the primary ovarian sites of previously untreated patients. All of the specimens were anonymous and tissues were obtained in compliance with institutional review board regulations. Patient features and tumor characteristics for this study are reported in Tables I and II. On follow-up, 26 patients survived, 59 patients were deceased, and 11 patients were lost, adding up to a follow-up rate of 88.54%. Follow-up records until December 2012 (from 9 to 120 months) are presented, with a mean follow-up time of 60.03 months.
The immunohistochemical staining was carried out by cutting out 4-µm sections from the formaldehyde-fixed and paraffin-embedded tissue specimens. The tissue sections were baked, deparaffinized with xylene, and rehydrated through a After the viral production, the medium was filtered through a 0.45-µm filter.
The ovarian cancer cells were infected at ~70% confluence in DMEM medium containing 8 µg/ml of polybrene. After a 24-h culture, the medium was replenished with fresh medium. Then the stable cell lines were selected using 2 µg/ml puromycin for two weeks. The knockdown efficiency was determined by both western blotting and qRT-PCR.
Gene expression analysis (RNA isolation, quantitative realtime PCR)
. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The cDNAs were synthesized from total RNA using the SuperScript™ II Reverse Transcriptase kit (Invitrogen). PCR was carried out using SYBR ® Green Realtime PCR master mix (code no. QPK-201, Toyobo Co., Ltd.). The thermal cycling conditions were maintained at an initial denaturation at 95˚C for 30 sec, followed by 40 cycles of PCR using the following profile: 94˚C, 5 sec; 60˚C, 10 sec; and 72˚C, 15 sec. GAPDH was used as a control of normalization, the primers used for qRT-PCR are listed in Table III .
Western blot analysis. The cells were collected and lysed in lysis buffer, the boiled lysates were resolved by SDS-PAGE and then blotted onto PVDF membrane. Afer incubating with primary antibodies against SREBP1, FASN, ACLY, SCD, ACAC (Abcam) and β-actin (#IE9A3 ZSGB-BIO). The membranes were incubated with appropriate horseradish peroxidase-labeled secondary antibodies and visualized by ECL Plus system (Amersham Life Sciences, Piscataway, NJ, USA). Quantitative data were assigned using a computing densitometer with Image-Pro Plus software.
Cell apoptosis and cell cycle assays. Cell apoptosis was performed by Annexin V-FITC/PI apoptosis detection kit (BD Biosciences Clontech) following manufacturer's instructions. Cell cycle was determined by RNase A and PI. The mixture was immediately subjected to cell apoptosis analysis and cell cycle assays on FACS calibur flow cytometer (BectonDickinson, Franklin Lakes, NJ, USA).
Cell proliferation, transwell migration and invasion assay. For cell proliferation assay using the Cell Counting Kit-8 (CCK-8), cells (2x10³ cells per well) were seeded on 96-well plates for 5-day incubation. Then cells were harvested and numbered by enzyme-linked immunosorbent assay (ELISA) reader. The 24-well transwell cell culture chambers were utilized to examine in vitro cell migration and invasion of ovarian cancer cells. Briefly, the undersides of the upper chambers were precoated with extracellular matrix (ECM) gel (1:4 dilution, for invasion assay) or not (for migration assay). Cells (1x10 5 ) were seeded inside the precoated upper chambers. After 24 h of incubation, the numbers of migrated or invading cells were measured by the crystal violet staining method.
Mouse xenograft experiments.
In order to analyze the tumorigenic potential of SREBP1, Female (4-6 weeks old) SCID mice were purchased from Medical College of Peking University and all animal work was performed in conformity with the National Institutes of Health Guide for Care and Use of Laboratory Animals (publication no. 85-23, revised 1985). The mice were subcutaneously inoculated with highly metastatic HO8910PM cells in the axillary fossa. Comparisons were made among control-shRNA, shRNA-#1 and shRNA-#3 groups (3x10 6 cells/mouse) with 9 mice in each group. The tumor volume was calculated using the following equation: V = a x b 2 /2, where a and b represented the longest and shortest diameter of the tumor, respectively. At the time of sacrifice, tumors were excised, weighed and preserved in order to perform further experiments.
Statistical analysis. For in vitro experiments, results are presented as means ± standard deviation (SD). Least significant difference t test (LSD-t) and t-test were performed for group comparison. An exponential regression model was performed for estimate of in vivo experiment. Fisher's exact tests for contingency tables were used in Tables I and II . The relative risk of death from ovarian cancer was evaluated through the Cox proportional hazards regression model. Kaplan-Meier survival curves were used and significance was assessed by the Log-rank test. The overall survival was also compared by Log-rank test. For all of the statistical tests, all P-values were 2-sided and P<0.05 was defined as statistically significant. In all cases, SPSS 17.0 software (SPSS Inc., Chicago, IL) was used.
Results
Increased SREBP1 protein expression in ovarian cancer.
We performed immunohistochemical (IHC) staining on different subtypes of ovarian cancer specimens and observed Table I ]. The more aggressive phenotypes of ovarian cancer have more intensive staining of SREBP1 ( Fig. 2A-C) . However, SREBP1 expression did not show any significant correlation with pathological type, patient age, lymph node metastasis or ascitic cytology (Table II) . Elevated expression of nuclear SREBP1 in ovarian cancer was observed, however it did not show any significant correlation with the clinicopathological parameters, which may be due to the size of the patient cohort. These results suggest that SREBP1 is overexpressed in ovarian cancer, which may contribute to cancer progression. showed a lower staining of SREBP1, but G3 (C) showed higher density staining (immunohistochemical staining, x400). G1 (D) and G2 (E) showed a lower staining of FASN, but G3 (F) showed higher density staining (immunohistochemical staining, x400).
classification, pathologic stage, ascitic cytology, lymphatic metastasis, age, FASN and SREBP1 expression appeared to be independent factor in predicting the overall survival in ovarian cancer patients.
SREBP1 is responsible for lipogenic gene expression in ovarian cancer cells.
We performed the initial screening for SREBP1 expression in four aforementioned ovarian cancer cell lines. SREBP1 expression was almost undetectable in the 3AO cells, moderately expressed in SKOV3 cells and highly expressed in A2780 and HO8910PM cells (Fig. 4A) . SREBP1 downstream target genes FASN, ACLY, ACAC and SCD1 were also highly expressed in HO8910PM. HO8910PM cell line was selected for most of the experiments in this study (13) . To verify whether the endogenous SREBP1 is required for lipogenic gene expression, we constructed four shRNA expression vectors (#1-3 and control-vector) targeting SREBP1, and transfected them into HO8910M cells. A high knockdown efficiency of SREBP1 expression was observed by Western blot and real-time PCR in vectors #2 and #3 (Fig. 4B-D) . Simultaneous reduction in the expression of SREBP1 target genes indicated an SREBP1-dependent expression of these genes (Fig. 4B-D) .
SREBP1 regulation of cellular proliferation, migration, invasion and apoptosis.
In order to compare cell proliferation rate among cells with knockdown of SREBP1, lipid-free culture medium was used to culture shRNA-#1, shRNA-#3 and control-shRNA cells. Statistical analysis indicated a significant reduction of cell proliferation in shRNA-#3 group compared to control-shRNA (P<0.05) (Fig. 5A) . We also found that knockdown of SREBP1, though attenuating cell growth, had no significant influence on a specific phase of the cell cycle. These observations suggested that the depletion of SREBP1 may increase the overall cell cycle duration.
As shown in Fig. 5B , the rate of late apoptosis in the shRNA-#3 group (11.68±0.27%) was significantly higher than that of the control-shRNA group (8.17±0.66%) (P<0.001) (Fig. 5C ). Cells in early apoptosis were low in all three cell lines, which showed an increase from 5.27% in control-shRNA group to 9.34% in shRNA-#3 group (P<0.01) (Fig. 5C) . Next, we analyzed the migratory and invasive properties of SREBP1 knockdown cells. We found a significantly reduced number of (Fig. 5D ). These data revealed that SREBP1 functions in regulating cell migration and invasion of ovarian cancer cells.
Knockdown of SREBP1 impairs ovarian tumor growth in vivo.
The xenograft female SCID mouse model exhibited a markedly slowed growth pattern at 10 days after tumor cell inoculation of shRNA-#3 group (Fig. 6A and B) . Control-shRNA and shRNA-#1 groups were consistent with comparatively larger tumors (Fig. 6C) . The shRNA-#3 group showed a significant inhibition of tumor growth (P<0.001). These results demonstrate that SREBP1 plays an important role in tumor growth in vivo. Immunohistochemical analysis of tumor sections showed a decrease of the SREBP1 expression in tumors from shRNA-#3 groups compared to control-shRNA group (Fig. 7A) . As shown in Fig. 7B -D, the expression levels of SREBP1 and its downstream target genes were decreased in the tumors in #3 group.
Discussion
In cancer cells, de novo lipogenesis is closely related to increased synthesis of membranes, energy production and activation of intracellular signaling pathways during cell proliferation and division as well as cancer development and progression (14-16).
SREBPs are major transcriptional regulators of genes involved in de novo lipid synthesis and are critical for maintaining lipid homeostasis. SREBP1 overexpression or activation has been reported in hepatocellular carcinoma, colorectal carcinoma, breast, and prostate tumors (9) (10) (11) (12) . Despite this elaborate research, this is the first report on SREBP1 expression in ovarian cancer. In our study, we found that SREBP1 promoted ovarian cancer growth. SREBP1 expression levels were associated with clinicopathological parameters and with FASN expression. A previous study showed that the lipogenic gene, FASN, was overexpressed in ovarian cancers (17) . We anticipated that SREBP1 overexpression in ovarian cancer may contribute to enhanced FASN expression. The survival of patients who expressed high levels of SREBP1 was significantly reduced compared to the patients negative for SREBP1 expression. The cell culture and in vivo experimental data collectively suggest that SREBP1 expression plays an important role in regulation of ovarian tumor growth. The observation of SREBP1 overexpression in ovarian cancer further supports the notion that de novo lipid synthesis is required in tumor growth.
To further investigate potential function of SREBP1 in ovarian cancer, we conducted several biophysiological experiments using the shRNA knockdown approach targeting SREBP1. Our results confirmed that SREBP1 silencing in ovarian cancer cells inhibited cell growth, migration and invasion. Enhanced cell apoptosis further implies the mechanisms by which SREBP1 is required for tumor growth. The observation of cell proliferation was only made in cell culture in the presence of fat-depleted serum; where the cultured cells completely rely on the de novo lipogenesis to satisfy the demand for cholesterol and phospholipids of rapidly proliferating cells. Re-activation of de novo fatty acid synthesis emerges in many cancers, suggesting that lipogenesis may be a rate-limiting stage in rapidly growing tissues (18) . Induction of de novo lipid synthesis in response to Akt activation requires the activation of SREBP (19) . Furthermore, Akt acts as an anti-apoptotic signaling molecule and PI3K/Akt/ TOR pathway regulates lipid and protein biosynthesis. Both of these processes are critically required for cell growth (20) . Overactive Akt (often found in cancer) activates SREBP and increases lipid synthesis, promoting Akt signaling (21) . Thus SREBP1 expression by stimulating lipogenic genes, promotes cancer cell proliferation. This is the first report that systematically investigated the function of SREBP1 in ovarian cancer cell proliferation and tumor growth and may ultimately provides a novel therapeutic strategy in the therapeutic aspect of this disease.
Several proteins including FASN, ACAC, ACLY and SCD inlipogenic pathway have been reported to play important roles in tumor progression and potentially targeted in cancer therapy. Inhibition of the expression and activity of these genes with either interfering RNA or small molecule inhibitors restrain tumor cell proliferation in cell culture in vitro and tumor growth in vivo (22) (23) (24) (25) (26) (27) (28) (29) . Furthermore, chemical inhibitors of FASN have been shown to be effective in repressing tumor growth (30) . However, the efficacy of these genes in cancer therapy requires further investigation. Out results showed that silencing SREBP1 blocked the expression of SREBP1 target genes FASN, ACAC and ACLY at both protein and mRNA levels in cell culture. The effect of shRNA targeting SREBP1 was more significant in repressing the expression of FASN, ACAC and ACLY in mouse xenograft model in vivo. Our results demonstrated that as a master regulator of lipogenic gene transcription, SREBP1 regulates ovarian cancer cell growth and survival through accommodating downstream de novo lipogenic genes. The expression and activation of FASN, ACAC, ACLY and SCD could be regulated not only by transcription factor SREBP1 but also by other signal regulating pathways such as PI3K/ Akt and MAPK pathway in human (31) . Our study verified the significance of the lipogenic enzymes in ovarian cancer pathogenesis, however, the underlying mechanisms, through which SREBP1 regulates the downstream lipogenic genes in ovarian cancer cells, are still poorly understood.
In summary, we have confirmed that SREBP1 plays important roles in regulating lipid biosynthesis and homeostasis, promoting ovarian tumor growth. Although further investigations are needed to elucidate the molecular mechanisms underlying the overexpression of SREBP1 and its ancillary regulatory signaling pathways in cancers, our study suggests that SREBP1 may serve as a therapeutic target for antitumor therapy.
